Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 4 (2007), Issue 5 (May)

1. Improving the efficacy of trastuzumab in breast cancer.
   Cancer Sci, 98(6): 767-71. [Abstract] [Full-text]
2. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
   J Natl Cancer Inst, 99(9): 694-705. [Abstract] [Full-text]
3. Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer.
   Oncologist, 12(4): 390-6. [Abstract] [Full-text]
4. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials.
   Oncologist, 12(4): 375-89. [Abstract] [Full-text]
5. CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients.
   Clin Cancer Res, 13(9): 2714-21. [Abstract] [Full-text]
6. Managing cardiotoxicity in anthracycline-treated breast cancers.
   Expert Opin Drug Saf, 6(3): 315-21. [Abstract] [Full-text]
7. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis.
   CMAJ, 176(10): 1429-34. [Abstract] [Full-text]
8. Bs23 targeted therapy.
   ANZ J Surg, 77: A6. [Abstract] [Full-text]
9. Bs24 apoptosis: why surgeons need to understand it.
   ANZ J Surg, 77: A6. [Abstract] [Full-text]
10. Bs04 trastuzumab (herceptin): review of adjuvant trials in early breast cancer.
    ANZ J Surg, 77: A1. [Abstract] [Full-text]
11. Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.
    Expert Rev Mol Diagn, 7(3): 309-19. [Abstract] [Full-text]
12. Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells.
    J Virol, 81(11): 5705-13. [Abstract] [Full-text]
13. Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells.
    Br J Cancer, 96(10): 1520-5. [Abstract] [Full-text]
14. Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciences.
    Clin Pharmacol Ther, 81(6): 887-92. [Abstract] [Full-text]
15. Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu.
    Clin Cancer Res, 13(10): 2936-45. [Abstract] [Full-text]
16. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
    Cancer Epidemiol Biomarkers Prev, 16(5): 1026-31. [Abstract] [Full-text]
17. The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature.
    Diagn Cytopathol, 35(6): 319-28. [Abstract] [Full-text]
18. HER2-positive advanced breast cancer.
    Hematol Oncol Clin North Am, 21(2): 293-302. [Abstract] [Full-text]
19. Trastuzumab (herceptin) for early-stage breast cancer.
    Hematol Oncol Clin North Am, 21(2): 239-56. [Abstract] [Full-text]
20. Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy--Case report and updated literature review.
    Reprod Toxicol, 23(4): 611-3. [Abstract] [Full-text]
21. Grb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel.
    Int J Cancer, 121(2): 407-15. [Abstract] [Full-text]
22. Management and preparedness for infusion and hypersensitivity reactions.
    Oncologist, 12(5): 601-9. [Abstract] [Full-text]
23. Stepwise prediction of conformational discontinuous B-cell epitopes using the Mapitope algorithm.
    Proteins, 68(1): 294-304. [Abstract] [Full-text]
24. Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses.
    Cancer Treat Rev, 33(3): 230-83. [Abstract] [Full-text]
25. Trastuzumab: triumphs and tribulations.
    Oncogene, 26(25): 3637-43. [Abstract] [Full-text]
26. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.
    BMC Cancer, 7: 80. [Abstract] [Full-text]
27. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
    J Clin Oncol, 25(16): 2218-24. [Abstract] [Full-text]

© 2004-2010 Herceptin Research Today. All Rights Reserved.